1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Influenza Therapeutics Market
2.3. Global Influenza Therapeutics Market, By Therapy, 2025 (US$ Million)
2.4. Global Influenza Therapeutics Market, By Geography, 2025 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2025

3. Influenza Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Influenza Therapeutics Market Vendors
3.2. Strategies Adopted by Influenza Therapeutics Market Vendors

4. Influenza Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Influenza Therapeutics Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape

5. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Vaccines
5.3.1.1. Trivalent
5.3.1.2. Quadrivalent
5.3.2. Drugs
5.3.2.1. Zanamivir
5.3.2.2. Oseltamivir
5.3.2.3. Peramivir
5.3.2.4. Other

6. North America Influenza Therapeutics Market, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
6.3. Influenza Therapeutics Market: By Region, 2024-2034, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)

7. UK and European Union Influenza Therapeutics Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
7.3. Influenza Therapeutics Market: By Region, 2024-2034, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
7.3.1.5. France
7.3.1.5.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)

8. Asia Pacific Influenza Therapeutics Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
8.3. Influenza Therapeutics Market: By Region, 2024-2034, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
8.3.1.3. India
8.3.1.3.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)

9. Latin America Influenza Therapeutics Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
9.3. Influenza Therapeutics Market: By Region, 2024-2034, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)

10. Middle East and Africa Influenza Therapeutics Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
10.3. Influenza Therapeutics Market: By Region, 2024-2034, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Influenza Therapeutics Market: By Therapy, 2024-2034, USD (Million)

11. Company Profile
11.1. Abbott Laboratories (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Astrazeneca PLC
11.3. Biocryst Pharmaceuticals, Inc.
11.4. Chiron Corporation
11.5. CSL Limited
11.6. Daiichi Sankyo Co., Ltd.
11.7. Glaxosmithkline PLC
11.8. Mitsubishi Tanabe Pharma Corporation
11.9. Nanotherapeutics Inc.
11.10. Protein Sciences Corporation
11.11. Roche Holding AG
11.12. Sanofi SA
11.13. Shionogi & Co., Ltd.
11.14. Sinovac Biotech Ltd.